Alphatec (US:ATEC)2026-02-24 22:32Financial Data and Key Metrics Changes - In Q4 2025, the company reported revenue of $213 million, representing a 20% year-over-year growth and a 21% growth in surgical revenue [3][6] - For the full year 2025, total revenue reached $764 million, a $153 million increase year-over-year, equating to a 25% total revenue growth [4][16] - Adjusted EBITDA for Q4 was $33 million, reflecting a 61% year-over-year increase, with a margin of 16% [15][24] - The full year Adjusted EBITDA was $93 million, approximately 12% of sales, marking a significant improvement of $63 million year-over-year [17][24] Business Line Data and Key Metrics Changes - Surgical revenue in Q4 was $190 million, up 21% year-over-year, while EOS revenue was $23 million, up 14% year-over-year [6][8] - For the full year, surgical revenue totaled $687 million, a 26% increase compared to 2024, driven by a 22% growth in procedural volume [16][17] - EOS revenue for the full year was $77 million, reflecting a 15% year-over-year growth [16] Market Data and Key Metrics Changes - U.S. revenue per case increased by 1.4%, with lateral and cervical procedures both up 6% [7] - Same-store sales in the U.S. grew 20% year-over-year, indicating strong growth in established territories [8] Company Strategy and Development Direction - The company is focused on creating clinical distinction through proceduralization, particularly in lateral surgery, which is seen as a growth engine [26][29] - ATEC is expanding its sales force and enhancing its product offerings, including the introduction of advanced technologies like the Valence platform for intraoperative navigation [27][28] - The company aims to leverage its unique ecosystem to address complex pathologies in spine surgery, enhancing surgeon confidence and patient outcomes [30][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of top-line growth, driven by increasing surgeon adoption and procedural volume [9][19] - The outlook for 2026 anticipates revenue growth of 17% to approximately $890 million, with Adjusted EBITDA guidance increased to $134 million [19][24] - The company is positioned for long-term profitable growth, focusing on expanding its infrastructure and integrating data into surgical experiences [38][39] Other Important Information - The company ended Q4 with $161 million in cash and had access to an additional $60 million in undrawn credit, totaling $221 million in available cash [18] - Free cash flow for Q4 was $8 million, marking the first full year of positive free cash flow for the company [18][19] Q&A Session Summary Question: Concerns about share trading post-earnings - Management confirmed that Q4 results were in line with expectations, with EBITDA exceeding consensus by 10% and 2026 revenue guidance reaffirmed [44][45] Question: Cadence for 2026 revenue and EBITDA - Management indicated that Q1 revenue is expected to follow a similar seasonal pattern as 2025, with Q1 contributing about 22.1% of sales [47][48] Question: Attracting sales talent - Management stated that the hiring process is going well, with strong demand for the company's portfolio from both surgeons and sales personnel [53]